Publications
Publications
- All
- Antiviral
- IMU-856
- Other
- VidoCa IBD
- VidoCa Misc
- VidoCa MS
- VidoCa MS
Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data
Matej Ondrus, Robert J. Fox, Evelyn Peelen, Juliano Fonseca, Valentina Sciacca, Ines Sanchez-Gomez, Jacques Arend, Alexandra Herrmann, Maria Samcova, Christian Gege, Lesia Havrylova, Hella Kohlhof, Jason Tardio, Daniel Vitt, Andreas Muehler
Expert Opinion on Investigational Drugs
Published: July 16, 2026 - IMU-856
EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026 Symposium
Monday, June 22, 2026 – Thursday, June 25, 2026
Presentation MedChem Frontiers 2026 – IMU-856 for Gastrointestinal Disease Treatment
- VidoCa MS
Development of a Brain-Penetrant Nurr1 Agonist Tool
Jan Vietor, Tanja Stiller, Christian Gege, Wael Saeb, Úrsula López-García, Hella Kohlhof, Daniel Vitt, Daniel Merk
ChemMedChem
Published: June 14, 2026 - VidoCa MS
2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting
Wednesday, May 27, 2026 – Friday, May 29, 2026
- Other
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer
Rafael Grochot, Christina Guo, Suzanne Carreira, Mateus Crespo, Jon Welti, Susana Miranda, Ines Figueiredo, Claudia Bertan, Jan Rekowski, Wei Yuan, Nina Tunariu, Katarzyna Abramowicz, Ana Ferreira, Ruth Riisnaes, Antje Neeb, Bora Gurel, Maria de Los Dolores Fenor de la Maza, Khobe Chandran, Juliet Carmichael, Daniel Westaby, Hella Kohlhof, Adam Sharp, Alec Paschalis, Johann de Bono
European Urology Oncology
Published: March 11, 2026 - VidoCa MS
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026
Thursday, February 5, 2026 – Saturday, February 7, 2026
- VidoCa MS
Structural Tuning of Vidofludimus for High-Efficacy NR4A Agonism
Jan Vietor, Romy Busch, Úrsula López-García, Tanja Stiller, Anna Maria Thommes, Christian Gege, Daniel Merk
Journal of Medicinal Chemistry
Published: January 26, 2026 - Other
Selective disruption of RORγt-CBFβ interaction by IMU-935 prevents RORγt-dependent Th17 autoimmunity but not thymocyte development
Hongmin Wu, Xiancai Zhong, Ning Ma, Zhiheng He, Guanpeng Wang, Geming Lu, Yate-Ching Yuan, Wencan Zhang, Yun Shi, Nagarajan Vaidehi, Evelyn Peelen, Tanja Wulff, Christian Gege, Hella Kohlhof, Daniel Vitt, Yousang Gwack, Ichiro Taniuchi, Hai-Hui Xue, Zuoming Sun
The Journal of Clinical Investigation
Published: January 2, 2026 - VidoCa MS
17th International Congress of the International Society of Neuroimmunology (ISNI)
Sunday, October 5, 2025 – Wednesday, October 8, 2025
- IMU-856
UEGW 2025 – United European Gastroenterology Week
Sunday, October 5, 2025 – Wednesday, October 8, 2025
- VidoCa MS
41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Wednesday, September 24, 2025 – Friday, September 26, 2025
- Presentation ECTRIMS 2025 – Efficacy and Safety of Vidofludimus Calcium in Progressive Multiple Sclerosis Phase 2 CALLIPER
- Poster ECTRIMS 2025 – Efficacy and Safety of Vidofludimus Calcium in Primary Progressive Multiple Sclerosis Phase 2 CALLIPER
- Poster ECTRIMS 2025 – 144 Week Analysis Confirmed Disability Worsening Events Phase 2 EMPhASIS
- Poster ECTRIMS 2025 – Update Assessment Long-Term Safety and Tolerability Vidofludimus Calcium Phase 2 EMPhASIS
- Poster ECTRIMS 2025 – Potential Neuroprotective Activity by Vidofludimus Calcium in In Vivo Models
- VidoCa MS
Lost in translation: rethinking animal models of progressive MS (an industry perspective)
Florian Von Raison, Paola Zaratin, Martin Stangel, Derya Shimshek, Barbara Nuesslein-Hildesheim, Giuseppe Locatelli, Ludovic Collin, Lynette Foo, Mehrnoosh Jafari, Evelyn Peelen, Hella Kohlhof, Nellwyn Hagan, Daniela Piani Meier, Ursula Boschert, Marco Salvetti. On behalf of The Industry Forum of the International Progressive MS Alliance
Multiple Sclerosis and Related Disorders
Published: July 27, 2025 - VidoCa Misc
Inhibition of pyrimidine de novo synthesis fosters Treg cells and reduces diabetes development in models of Type 1 Diabetes
Hannah Hipp, Camilla Tondello, Hanna Gmehling, Lena K. Scholz, Antigoni Stavridou, Maike Becker, Anne-Marie Bührer, Edith Hintermann, Sandra M. Dirschl, Till M. Johannsmann, Martin G. Scherm, Hella Kohlhof, Isabelle Serr, Urs Christen, Carolin Daniel
Molecular Metabolism
Published: July 22, 2025 - VidoCa MS
Carboxylic Acid Bioisosteres Boost Nurr1 Agonist Selectivity
Tanja Stiller, Christian Gege, Wael Saeb, Jan Vietor, Ursula Lopez-Garcia, Romy Busch, Hella Kohlhof, Daniel Vitt, Daniel Merk
Journal of Medicinal Chemistry
Published: July 17, 2025 - VidoCa MS
11th Congress of the European Academy of Neurology (EAN) – Helsinki 2025
Saturday, June 21, 2025 – Tuesday, June 24, 2025
- VidoCa MS
Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2025
Wednesday, May 28, 2025 – Saturday, May 31, 2025
- VidoCa MS
Structural and mechanistic profiling of Nurr1 modulation by vidofludimus enables structure-guided ligand design
Úrsula López-García, Jan Vietor, Julian A. Marschner, Jan Heering, Vasily Morozov, Thomas Wein, Daniel Merk
Communications Chemistry
Published: May 21, 2025
https://doi.org/10.1038/s42004-025-01553-8 - IMU-856
Digestive Disease Week® (DDW)
Saturday, May 3, 2025 – Tuesday, May 6, 2025
- VidoCa MS
7th Neuroimmunology Drug Development Summit
Tuesday, February 25, 2025 – Thursday, February 27, 2025
- VidoCa MS
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025
Thursday, February 27, 2025 – Saturday, March 1, 2025
- IMU-856
19th Congress of ECCO (European Crohn’s and Colitis Organisation)
Friday, February 19, 2025 – Saturday, February 22, 2025
- VidoCa IBD
Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial
Geert D’Haens, Kalina Grivcheva Stardelova, Edite Sadiku, Natallia Kizlova, Syitlana Skybalo, Yulia Shehovtsova, Mirela Abramescu, Daniel Vitt, Hella Kohlhof, Andreas Muehler
Clinical and Translational Gastroenterology
Published: January 10, 2025
https://doi.org/10.14309/ctg.0000000000000813 - IMU-856
Symposium 238: Immuno-Mediated Diseases of the GI Tract: Where Do We Stand?
Friday, November 8, 2024 – Saturday, November 9, 2024
- IMU-856
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
A James M Daveson, Richard Stubbs, Thomas M Polasek, Jorma Isola, Robert Anderson, Jason A Tye-Din, Mark Schoeman, Claudette Lionnet, Swee Lin Chen Yi Mei, Jelena Mihajlović, Martina Wirth, Evelyn Peelen, Amelie Schreieck, Hella Kohlhof, Daniel Vitt, Andreas Muehler, Franziska Buriánek
The Lancet Gastroenterology & Hepatology
Published: November 6, 2024
https://doi.org/10.1016/S2468-1253(24)00248-6 - VidoCa MS
40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Wednesday, September 18, 2024 – Friday, September 20, 2024
- Poster ECTRIMS 2024 – Phase 2 CALLIPER NfL Interim Results
- Poster ECTRIMS 2024 – Potential Vidofludimus Calcium to Reduce Fatigue in MS by Preventing EBV Reactivation
- Poster ECTRIMS 2024 – Vidofludimus Calcium Nurr1 Activity in Preclinical Models
- Poster ECTRIMS 2024 – Vidofludimus Calcium T Helper Cell Modulatory Effects In Vivo
- VidoCa MS
Immunic’s Multiple Sclerosis R&D Day in New York City
Tuesday, September 10, 2024
- IMU-856
20th International Celiac Disease Symposium ICDS
Thursday, September 5, 2024 – Saturday, September 7, 2024
- VidoCa Misc
DMDG 50th Open Meeting 2024
Monday, September 2, 2024 – Wednesday, September 4, 2024
- IMU-856
New developments in celiac disease treatments
Franziska Buriánek, Christian Gege, Petar Marinković
Drug Discovery Today
Published: August 2024
https://doi.org/10.1016/j.drudis.2024.104113 - VidoCa MS
2024 Medicinal Chemistry Gordon Research Conference: Advancing Drug Discovery with Innovative Science and Technologies
Sunday, August 11, 2024 – Friday, August 16, 2024
- VidoCa MS
The Consortium of Multiple Sclerosis Centers (CMSC) 38th Annual Meeting
Wednesday, May 29, 2024 – Saturday, June 1, 2024
- IMU-856
Digestive Disease Week (DDW) 2024
Saturday, May 18, 2024 – Tuesday, May 21, 2024
- VidoCa MS
Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial
Robert J. Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Viktoriia Gryb, Konrad Rejdak, Plamen S. Bozhinov, Daniel Vitt, Hella Kohlhof, Jason Slizgi, Matej Ondrus, Valentina Sciacca, Andreas R. Muehler
Neurology® Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology
Published: April 25, 2024
https://doi.org/10.1212/NXI.0000000000200208 - VidoCa MS
Immunic’s MS R&D Day in San Francisco
Tuesday, April 9, 2024
- VidoCa MS
Frontiers in Medicinal Chemistry
Sunday, March 17, 2024 – Wednesday, March 20, 2024
- VidoCa MS
ACTRIMS Forum 2024
Thursday, February 29, 2024 – Saturday, March 2, 2024
- IMU-856
Association of European Coeliac Societies (AOECS) 35th General Assembly Conference 2023
Thursday, November 2, 2023 – Sunday, November 5, 2023
- IMU-856
UEG (United European Gastroenterology) Week 2023
Saturday, October 14, 2023 – Tuesday, October 17, 2023
- VidoCa MS
MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
Wednesday, October 11, 2023 – Friday, October 13, 2023
- VidoCa MS
16th International Congress of Neuroimmunology (ISNI)
Sunday, August 20, 2023 – Thursday, August 24, 2023
- IMU-856
Symposium 234: Mucosal Immunology – A Translational View into the Clinic
Thursday, July 6, 2023 – Saturday, July, 8, 2023
- VidoCa MS
Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023
Wednesday, May 31, 2023 – Saturday, June 3, 2023
- IMU-856
Digestive Disease Week 2023
Saturday, May 6, 2023 – Tuesday, May 9, 2023
- VidoCa MS
Development of a Potent Nurr1 Agonist Tool for In Vivo Applications
Jan Vietor, Christian Gege, Tanja Stiller, Romy Busch, Espen Schallmayer, Hella Kohlhof, Georg Höfner, Jörg Pabel, Julian A. Marschner, and Daniel Merk
Journal of Medicinal Chemistry
Published: April 26, 2023
https://doi.org/10.1021/acs.jmedchem.3c00415 - Other
Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study
Thomas M. Polasek, Indika Leelasena, Irina Betscheider, Marija Marolt, Hella Kohlhof, Daniel Vitt, Frank Fliegert, Andreas R. Muehler
Clinical Pharmacology in Drug Development
Published: March 20, 2023 - VidoCa MS
ACTRIMS Forum 2023
POSTER PRESENTATION
Thursday, February 23, 2023 – Saturday, February 25, 2023
- IMU-856
Immunic’s Celiac Disease R&D Webcast
Thursday, February 09, 2023
- Other
Outsourcing in Clinical Trials DACH 2022
Wednesday, November 30, 2022 – Thursday, December 1, 2022
- IMU-856
Australasian Pharmaceutical Science Association (APSA) and Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) 2022 Joint Conference
Tuesday, November 29, 2022 – Friday, December 2, 2022
- VidoCa MS
Immunic’s Multiple Sclerosis R&D Webcast
Thursday, November 17, 2022
- VidoCa Misc
Mechanistic Impact of Different Ligand Scaffolds on FXR Modulation Suggests Avenues to Selective Modulators
Jan Heering, Nathalie Jores, Whitney Kilu, Espen Schallmayer, Evelyn Peelen, Andreas Muehler, Hella Kohlhof, Daniel Vitt, Verena Linhard, Santosh L. Gande, Apirat Chaikuad, Sridhar Sreeramulu, Harald Schwalbe, Daniel Merk
ACS Chemical Biology
Published: November 1, 2022
https://doi.org/10.1021/acschembio.2c00599 - VidoCa MS
38th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Wednesday, October 26, 2022 – Friday, October 28, 2022
- IMU-856
19th International Celiac Disease Symposium (ICDS)
Wednesday, October 19, 2022 – Saturday, October 22, 2022
- IMU-856
IMU-856: Phase 1 SAD/MAD Data in Healthy Human Subjects
Tuesday, September 20, 2022
- Other
B & T Cell-Mediated Autoimmune Disease Drug Development Summit
Tuesday, July 26, 2022 – Thursday, July 28, 2022
- Other
16th World Immune Regulation Meeting
Wednesday, July 6, 2022 – Saturday, July 9, 2022
- VidoCa MS
A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis
Robert J. Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Viktoriia Gryb, Konrad Rejdak, Plamen Stoyanov Bozhinov, Nataliya Tomakh, Iryna Skrypchenko, Andreas R. Muehler
Annals of Clinical and Translational Neurology
Published: June 14, 2022
https://doi.org/10.1002/acn3.51574 - Other
13th International Congress on Autoimmunity
Friday, June 10, 2022 – Monday, June 13, 2022
- VidoCa Misc
A Pilot Study of Vidofludimus Calcium for Treatment of Primary Sclerosing Cholangitis
Elizabeth J. Carey, John Eaton, Mitchell Clayton, Andrea Gossard, Sara Iqbal, Hamid Ullah, Nan Zhang, Richard Butterfield, Keith D. Lindor
Hepatology Communications
Published: March 3, 2022
https://doi.org/10.1002/hep4.1926 - VidoCa IBD
17th Congress of ECCO (European Crohn’s and Colitis Organization)
Wednesday, February 16, 2022 – Saturday, February 19, 2022
- Other
IMU-935: Phase 1 SAD/MAD Data in Healthy Human Subjects and Preclinical Update
Tuesday, December 14, 2021
- VidoCa MS
37th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Wednesday, October 13, 2021 – Friday, October 15, 2021
- VidoCa IBD, VidoCa MS
B&T Cell-Mediated Autoimmune Disease Drug Development Summit
Wednesday, October 6, 2021
- Other
50th Annual European Society for Dermatological Research (ESDR) Meeting
Wednesday, September 22, 2021 – Saturday, September 25, 2021
- Other
Virtual R&D Day: Update on the Preclinical and Clinical Development of IMU-935
Monday, July 12, 2021
- Other
The International Federation of Psoriasis Association’s 6th World Psoriasis & Psoriatic Arthritis Conference 2021
Wednesday, June 30, 2021 – Saturday, July 3, 2021
- VidoCa MS
2021 Virtual AAN Annual Meeting
Saturday, April 17, 2021 – Thursday, April 22, 2021
- IMU-856
Clinical Relevance of Intestinal Barrier Dysfunction in Common Gastrointestinal Diseases
Andreas Muehler, Jason R. Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen, Daniel Vitt
World Journal of Gastrointestinal Pathophysiology
Published: December 12, 2020
https://doi.org/10.4291/wjgp.v11.i6.114 - VidoCa MS
MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting
Friday, September 11, 2020 – Sunday, September 13, 2020
- Other
Immunic’s Inaugural Virtual R&D Day
Tuesday, May 19, 2020
- VidoCa MS
Vidofludimus Calcium, a Next Generation DHODH Inhibitor for the Treatment of Relapsing-Remitting Multiple Sclerosis
Andreas Muehler, Evelyn Peelen, Hella Kohlhof, Manfred Gröppel, Daniel Vitt
Multiple Sclerosis and Related Disorders
Published: May 6, 2020
https://doi.org/10.1016/j.msard.2020.102129 - VidoCa Misc
Safety, Tolerability and Pharmacokinetics of Vidofludimus Calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt
European Journal of Drug Metabolism and Pharmacokinetics
Published: May 2, 2020
https://doi.org/10.1007/s13318-020-00623-7 - VidoCa MS
Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis (4558)
Robert Fox, Heinz Wiendl, Nicola De Stefano, Johann Sellner, Andreas Mühler
Neurology
Published: April 14, 2020 - IMU-856
IBD Innovate Conference: Product Development for Crohn’s and Colitis
Wednesday, December 4, 2019
New York - VidoCa IBD
United European Gastroenterology Week (UEGW)
Tuesday, October 22, 2019
Barcelona, Spain - VidoCa Misc
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt
Drugs in R&D
Published: October 16, 2019
https://doi.org/10.1007/s40268-019-00286-z - VidoCa MS
Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019
Wednesday, September 11, 2019
Stockholm, Sweden - VidoCa IBD
GI Inflammatory Diseases Summit (GIIDS)
Monday, June 24, 2019
Boston